Summary of Significant Accounting Policies (Tables)
|
3 Months Ended |
Mar. 31, 2020 |
| Accounting Policies [Abstract] |
|
| Disposal Groups, Including Discontinued Operations [Table Text Block] |
| | |
March 31,
2020 | | |
December 31,
2019 | |
| Cash and cash equivalents | |
$ | 12,204,569 | | |
$ | 16,350,237 | |
| Restricted cash | |
| 171,593 | | |
| 174,950 | |
| Total cash, cash equivalents and restricted cash | |
$ | 12,376,162 | | |
$ | 16,525,187 | |
|
| Marketable Securities [Table Text Block] |
| | |
Amortized Cost | | |
Gross Unrealized Losses | | |
Gross Unrealized Gains | | |
Fair Value | |
| March 31, 2020: | |
| | |
| | |
| | |
| |
| | |
| | |
| | |
| | |
| |
| Money Market Funds included in Cash Equivalents | |
$ | 1,567,300 | | |
$ | - | | |
$ | - | | |
$ | 1,567,300 | |
| U.S. Government Agency Securities | |
| 1,697,380 | | |
| - | | |
| 8,249 | | |
| 1,705,629 | |
| Corporate Securities | |
| 7,348,280 | | |
| (15,384 | ) | |
| 710 | | |
| 7,333,606 | |
| Commercial Paper | |
| 1,942,894 | | |
| (65 | ) | |
| 1,126 | | |
| 1,943,955 | |
| Subtotal | |
| 10,988,554 | | |
| (15,449 | ) | |
| 10,085 | | |
| 10,983,190 | |
| Total March 31, 2020 | |
$ | 12,555,854 | | |
$ | (15,449 | ) | |
$ | 10,085 | | |
$ | 12,550,490 | |
| | |
| | | |
| | | |
| | | |
| | |
| December 31, 2019: | |
| | | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | | |
| | |
| Money Market Funds included in Cash Equivalents | |
$ | 3,472,043 | | |
$ | - | | |
$ | 51 | | |
$ | 3,472,094 | |
| U.S. Government Agency Securities | |
| 2,691,091 | | |
| (42 | ) | |
| 869 | | |
| 2,691,918 | |
| Corporate Securities | |
| 6,058,265 | | |
| (1,438 | ) | |
| 440 | | |
| 6,057,267 | |
| Commercial Paper | |
| 3,234,583 | | |
| (16 | ) | |
| 405 | | |
| 3,234,972 | |
| Subtotal | |
| 11,983,939 | | |
| (1,496 | ) | |
| 1,714 | | |
| 11,984,157 | |
| Total December 31, 2019 | |
$ | 15,455,982 | | |
$ | (1,496 | ) | |
$ | 1,765 | | |
$ | 15,456,251 | |
|
| Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] |
| | |
Carrying Value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
| March 31, 2020: | |
| | |
| | |
| | |
| |
| | |
| | |
| | |
| | |
| |
| Money Market Funds and Cash Equivalents | |
$ | 1,567,300 | | |
$ | 1,567,300 | | |
$ | - | | |
$ | - | |
| U.S. Government Agency Securities | |
| 1,705,629 | | |
| 1,705,629 | | |
| - | | |
| - | |
| Corporate Securities | |
| 7,333,606 | | |
| - | | |
| 7,333,606 | | |
| - | |
| Commercial Paper | |
| 1,943,955 | | |
| - | | |
| 1,943,955 | | |
| - | |
| Subtotal | |
| 10,983,190 | | |
| 1,705,629 | | |
| 9,277,561 | | |
$ | - | |
| Total March 31, 2020 | |
$ | 12,550,490 | | |
$ | 3,272,929 | | |
$ | 9,277,561 | | |
$ | - | |
| | |
| | | |
| | | |
| | | |
| | |
| December 31, 2019: | |
| | | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | | |
| | |
| Money Market Funds and Cash Equivalents | |
$ | 3,472,094 | | |
$ | 3,472,094 | | |
$ | - | | |
$ | - | |
| U.S. Government Agency Securities | |
| 2,691,918 | | |
| 2,691,918 | | |
| - | | |
| - | |
| Corporate Securities | |
| 6,057,267 | | |
| - | | |
| 6,057,267 | | |
| - | |
| Commercial Paper | |
| 3,234,972 | | |
| - | | |
| 3,234,972 | | |
| - | |
| Subtotal | |
| 11,984,157 | | |
| 2,691,918 | | |
| 9,292,239 | | |
| - | |
| Total December 31, 2019 | |
$ | 15,456,251 | | |
$ | 6,164,012 | | |
$ | 9,292,239 | | |
$ | - | |
|
| Schedule Of Other Prepaid Expense [Table Text Block] |
| | |
March 31,
2020 | | |
December 31,
2019 | |
| Refundable regulatory fee | |
$ | 2,942,965 | | |
$ | - | |
| Insurance expense | |
| 246,464 | | |
| 244,828 | |
| Subscription fees | |
| 183,734 | | |
| 97,983 | |
| Software costs | |
| 104,597 | | |
| 10,081 | |
| Other | |
| 84,212 | | |
| 93,523 | |
| Total | |
$ | 3,561,972 | | |
$ | 446,415 | |
|
| Schedule of Inventory, Current [Table Text Block] |
| | |
March 31,
2020 | | |
December 31,
2019 | |
| Raw materials | |
$ | 6,893 | | |
$ | 6,893 | |
| Finished goods | |
| 418,178 | | |
| 461,735 | |
| Inventory reserve | |
| (130,163 | ) | |
| (130,163 | ) |
| Total | |
$ | 294,908 | | |
$ | 338,465 | |
|
| Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] |
| | |
March 31, 2020 | | |
December 31, 2019 | |
| Professional and consulting fees | |
$ | 287,560 | | |
$ | 214,777 | |
| Accrued payroll and payroll taxes | |
| 660,243 | | |
| 1,287,047 | |
| Clinical trial related | |
| 2,455,141 | | |
| 2,435,953 | |
| Manufacturing development related | |
| 1,000,904 | | |
| 806,032 | |
| Other | |
| 67,047 | | |
| 56,677 | |
| Total | |
$ | 4,470,895 | | |
$ | 4,800,486 | |
|
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] |
| | |
Three Months Ended March 31, | |
| | |
2020 | | |
2019 | |
| | |
(Number of Shares of Common Stock Issuable) | |
| Series C non-voting preferred stock | |
| 104,000 | | |
| 408,000 | |
| Series D non-voting preferred stock | |
| - | | |
| 295,848 | |
| Series E non-voting preferred stock | |
| 391,953 | | |
| 391,953 | |
| Series F non-voting preferred stock | |
| - | | |
| 2,469,137 | |
| Series G non-voting preferred stock | |
| 5,560,137 | | |
| - | |
| Shares issuable upon conversion of convertible debt | |
| - | | |
| 1,000,000 | |
| Restricted stock units | |
| 417 | | |
| 19,917 | |
| Shares issuable for payment of deferred board compensation | |
| 35,303 | | |
| 29,427 | |
| Shares underlying outstanding warrants | |
| 183,148 | | |
| 3,199,788 | |
| Shares underlying outstanding stock options | |
| 1,720,937 | | |
| 1,212,974 | |
| Total potentially dilutive shares | |
| 7,995,895 | | |
| 9,027,044 | |
|